Logo

Celgene Reports Update on its Collaboration with Jounce Therapeutics

Share this

Celgene Reports Update on its Collaboration with Jounce Therapeutics

Shots:

  • Jounce to receive $50M up front- $180M as development & regulatory milestones- $300M as commercial milestones- royalties on global sales and will retain WW rights to its pipeline including vopratelimab- JTX-4014 and all discovery programs
  • Celgene to get WW rights to develop & commercialize Jounce’s JTX-8064- an anti-leukocyte immunoglobulin like receptor B2 (LILRB2) Ab- focuses on tumor-associated macrophages. Additionally- Celgene signed a mutual agreement with Jounce to terminate its 2016 deal which focuses on the development of immuno-oncology therapies
  • Jounce’s vopratelimab is a mAb JTX-4014 targeting ICOS- a protein present on the surface of T-cells found in solid tumors- assessed in ICONIC P-I/II study. JTX-4014 is an IgG4 mAb designed to block binding to PD-L1 and PD-L2 being evaluated in P-I study

Click here to­ read full press release/ article | Ref: GlobeNewsWire | Image: The Street


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions